Skip to content

Transcatheter arterial micro-embolization for chronic post surgical pain after total knee arthroplasty

Efficucy and safty of transcatheter arterial micro-embolization for chronic post surgical pain after total knee arthroplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs061220039
Enrollment
20
Registered
2022-07-06
Start date
2022-10-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cronic post-surgical pain after total knee arthroplasty total knee arthroplasty/ chronic post-surgical pain

Interventions

transcatheter arterial micro-embolization: TAME

Sponsors

Sugimura Natsuki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria will be eligible. (1) Patients who have undergone total knee arthroplasty (TKA) for osteoarthritis (OA) for at least one year at the time of consent. (2) Patients with a pain VAS of 30 or higher at the time of consent. (3) Patients whose age at the time of consent acquisition is between 50 and 90 years old. (4) Patients with poor improvement after conservative therapy (NSAID patch, education, exercise therapy) for at least 3 months prior to obtaining consent (pain VAS 30 or higher). (5) Patients with pain VAS of 30 or more at the time of crossover group transition

Exclusion criteria

Exclusion criteria: Patients who meet at least one of the following criteria will be excluded from the study. Patients who meet any one of the following criteria will not be allowed to participate in this study. (1) Patients with active indications for surgical treatment (e.g. aseptic loosening) (2) Patients with any of the following conditions: infection, rheumatoid arthritis, or mental illness. (3) Patients with poor alignment (4) Patients with actively suspected pain due to spinal lesions (5) Patients with a high psychogenic predisposition to pain (6) Patients with poorly controlled diabetesmellitus (7) Patients taking antithrombotic medication which can not be suspended (8) Patients with severely impaired renal function (9) Patients with bronchial asthma (10) Patients taking biguanide hypoglycemic agents which can not be suspended (11) Patients taking valproic acid (12) Patients with allergy to IPM/CS or contrast media (13) Patients who are difficult to follow up in the hospital during the follow up period. (14) Patients deemed ineligible by the physician.

Design outcomes

Primary

MeasureTime frame
Difference in change from baseline in WOMAC pain subscale at 3 months between the two groups

Secondary

MeasureTime frame
The conservative therapy group (Group C) will be converted to the crossover group (Group CX) using TAME if the pain persists after 3 months and the patient has hope for TAME. (1) TAME group vs. C group: pain VAS, WOMAC score (pain, stiffness, functional subscale, total score), and Central Sensitization Inventory (CSI) at 1, 4 weeks, 3, 6, and 12 months, difference in change from baseline in total PD score between the two groups (excluding WOMAC pain subscale at 3 months) (2) TAME group vs. CX group: pain VAS, WOMAC score (pain, stiffness, functional subscale, total score), Central Sensitization Inventory ( CSI), and total PD score from baseline. (3) Difference in values of pain VAS, WOMAC score, CSI, and total PD score at 1 year after TAME from baseline in each of the two groups(group TAME, group CX). (4) Concordance rate between synovitis (US-PD) and neovascularization (contrast findings) at TAME.

Contacts

Public ContactNatsuki Sugimura

Kochi Medical School Hospital

sugimura.n@kochi-u.ac.jp+81-88-880-2386

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026